Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Consolidated Net Income (2019 - 2026)

Immunome filings provide 4 years of Consolidated Net Income readings, the most recent being -$59.3 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 32.92% to -$59.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$238.8 million, a 9.48% decrease, with the full-year FY2025 number at -$224.1 million, up 26.71% from a year prior.
  • Consolidated Net Income hit -$59.3 million in Q1 2026 for Immunome, up from -$72.9 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$4.5 million in Q1 2023 to a low of -$132.3 million in Q1 2024.
  • Median Consolidated Net Income over the past 4 years was -$50.5 million (2024), compared with a mean of -$53.8 million.
  • Biggest five-year swings in Consolidated Net Income: plummeted 2859.05% in 2024 and later surged 66.26% in 2025.
  • Immunome's Consolidated Net Income stood at -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then grew by 12.18% to -$72.9 million in 2025, then increased by 18.57% to -$59.3 million in 2026.
  • The last three reported values for Consolidated Net Income were -$59.3 million (Q1 2026), -$72.9 million (Q4 2025), and -$60.1 million (Q3 2025) per Business Quant data.